Alimera Sciences announces expansion agreement with Horus Pharma
Alimera Sciences announces that it has expanded its relationship with Horus Pharma, one of the Company's current distributors of ILUVIEN in Europe. Following the successful launch of ILUVIEN for diabetic macular edema in France by Horus Pharma, Alimera Sciences and Horus have agreed to expand their relationship to introduce ILUVIEN for both DME and non-infectious posterior uveitis in the Benelux countries of Belgium, the Netherlands and Luxembourg. Horus Pharma estimates that there are approximately 70,000 patients within the Benelux countries who may be affected by DME. With ILUVIEN approved for both DME and NIPU in the Benelux, Horus will undertake the process of applying for reimbursement in each Benelux nation for each indication over the next 12-18 months.